This page shows what was measured, who it was measured in, and what that does not settle.
What Quercetin does in the body
Marketed for allergy and immunity; investigated as a senescent-cell killer
Two stories. As a supplement, quercetin is a broad weak inhibitor of a great many enzymes and a stabiliser of the cells that release histamine, which is where the allergy claim comes from. As a senolytic, it is used with dasatinib to disable the survival proteins that keep senescent cells alive when they should have died, so that those cells self-destruct. The senolytic use is a combination with a prescription drug, in supervised trials, and is not what is in a bottle on a shelf.
What happened in people
Systolic blood pressure -3.04 mmHg and diastolic -2.63 mmHg against placebo across 587 patients in seven trials
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
The senolytic programme is genuine, ongoing and among the more interesting things in ageing biology — and it is a supervised two-drug combination, not a supplement regimen
Where it acts
Adipose tissue and vascular endothelium, in the trials that measured tissue directly
Kind of result
A number that stands in for health
Supervision
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 9IKM0I5T1E · read 2026-08-29
The supplement label database classes it as botanical, under the name Quercetin.
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 116 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved3 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Recovery
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Focus
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Blood sugar
glucose tolerance following a maltose tolerance test; insulin sensitivity; glucose tolerance
Healthy ageing
frailty; mortality rate
Recovery
complete recovery from covid 19 resolution of symptoms
Focus
montreal cognitive assessment
Pain
pain intensity
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
3 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Percentage change in the bone resorption marker CTx at 20 weeks
✗ The study did not show it
Who was studied
Khosla 2024 (intermittent dasatinib plus quercetin, postmenopausal women)
How many people
60
Study design
Phase 2 randomised controlled trial
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
P = 0.611
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No serious adverse events. The positive findings were exploratory and restricted to the highest tertile of T cell p16 mRNA, which is a subgroup analysis and is presented as hypothesis-generating by the authors.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of quercetin aglycone, dihydrate or phytosome complex
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Retention rate and completion rate for planned clinical assessments
✓ The study showed what it set out to show
Who was studied
Justice 2019 (dasatinib plus quercetin, idiopathic pulmonary fibrosis)
How many people
14
Study design
Two-centre open-label first-in-human
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Not applicable — the primary endpoints were feasibility measures, not efficacy
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. One serious adverse event was reported. Non-serious events were primarily mild to moderate and predominantly respiratory. Retention was 100%.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of quercetin aglycone, dihydrate or phytosome complex
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Weighted mean difference in systolic and diastolic blood pressure
✓ The study showed what it set out to show
Who was studied
Serban 2016 pooled analysis (seven placebo-controlled trials, nine arms)
How many people
587
Study design
Systematic review and meta-analysis
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
P = 0.028 systolic, P < 0.001 diastolic
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The authors flagged that clinical relevance of a 3 mmHg systolic reduction remains to be established, and that the effect appeared confined to doses above 500 mg/day.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of quercetin aglycone, dihydrate or phytosome complex
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 4 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.2 registered measures of this kind. No reviewed result.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.1 registered measure of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.1 registered measure of this kind.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.2 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.8 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in C. elegans (roundworm), Drosophila (fruit fly), Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Quercetin
What a person takes: Oral capsule of quercetin aglycone, dihydrate or phytosome complex.
The measurement behind this step
Sold as a dietary supplement with no premarket efficacy review. Formulation matters more than the label suggests: plain aglycone, rutin and phospholipid phytosome complexes differ substantially in absorption, and the senolytic trials used a defined phytosome preparation. In those trials it is co-administered with dasatinib, a prescription-only tyrosine kinase inhibitor.
Getting in
Absorbed as an aglycone after the sugar is removed
Dietary quercetin arrives with a sugar attached, which has to come off before the body can absorb it.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Quercetin glycosides are hydrolysed by lactase phlorizin hydrolase at the brush border or by cytosolic beta-glucosidase after transport. Supplement aglycone bypasses this and is absorbed less efficiently in water, which is why phytosome and phospholipid complexes are used in the trials.
The liver tags most of it immediately, so what circulates is largely the modified form.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Extensive glucuronidation, sulfation and methylation give quercetin-3-glucuronide and isorhamnetin conjugates as the dominant plasma species. Whether these are active, or are deconjugated at inflamed tissue, remains unresolved.
It binds many proteins weakly, which is both the mechanism and the problem
Quercetin touches a great many enzymes loosely rather than one strongly, and some of those interactions are artefacts of how the tests are run.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Reported activities include PI3K, Src-family and other kinase inhibition, mast cell stabilisation, and inhibition of anti-apoptotic BCL-2 family proteins including BCL-xL, which is the senolytic-relevant one. Quercetin is also a documented pan-assay interference compound: it is redox-active, aggregates and quenches fluorescence.
In the senolytic combination, worn-out cells lose their survival signal
Together with dasatinib, quercetin disables the proteins that keep senescent cells from dying, so they self-destruct.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The senescent cell anti-apoptotic pathway network keeps senescent cells alive despite pro-apoptotic signalling. Dasatinib targets ephrin-dependent survival in one senescent cell type and quercetin targets BCL-xL and PI3K-dependent survival in another, which is the stated rationale for pairing them rather than using either alone.
Senescent cells fall in biopsy; the clinical endpoint has not followed
Fat biopsies show fewer worn-out cells. The first properly controlled trial of what that does to bone found nothing on its main measure.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Hickson et al. measured the biological effect directly in nine patients. Khosla et al. then tested whether it produces a clinical effect: CTx at 20 weeks did not differ between arms (P = 0.611). The mechanism is real and its clinical consequence is unproven, which is precisely the boundary this page exists to mark.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
environmental symptoms questionnaire at high altitude
pain intensity
Measured
Things only a test, a scale or a device shows.
plasma il 6
brachial artery flow mediated dilation
glucose tolerance following a maltose tolerance test
inflammatory markers
serum zinc before and after treatment
insulin sensitivity
glucose tolerance
systolic blood pressure
Meaningful
Things that change how a life goes, not only a number.
mortality rate
gait speed
survival rate
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (27)
lake louise ams scoring system at high altitude
army physical fitness test at high altitude
uphill hike at high altitude
frailty
oxidative stress markers
feasibility number of enrolled per month
eligibility proportion eligible after screening
c terminal telopeptide of type i collagen
days of stay at hospital after treatment and discharge
safety and tolerability
need for icu admission
treatment safety
complete recovery from covid 19 resolution of symptoms
admission to a hospital for further advanced treatment
osteocalcin
il 6
tnf alpha
neurovascular coupling
executive function
montreal cognitive assessment
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults taking it for seasonal allergy or immune support, and separately a small number of trial participants receiving it alongside dasatinib under supervision.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
The phase 2 randomised senolytic trial in 60 postmenopausal women missed its primary bone resorption endpoint (P = 0.611)
The endurance effect does not scale with achieved plasma concentration, which is not how a pharmacological effect normally behaves
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment.
On this record: Dietary quercetin arrives with a sugar attached, which has to come off before the body can absorb it.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
The product may not be what it says
Contents of a sold product are not always what the label states.
On this record: This is sold as a supplement, so no agency checked what is in a given tub before it was sold.
Other reasons RNAWiki checked and found nothing for (8)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Varies by country
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral capsule of quercetin aglycone, dihydrate or phytosome complex
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
The identity record classes it as a supplement ingredient; no medicines register records an approval.
No source is stored against this line.
What is in the pack
Sold as a dietary supplement with no premarket efficacy review. Formulation matters more than the label suggests: plain aglycone, rutin and phospholipid phytosome complexes differ substantially in absorption, and the senolytic trials used a defined phytosome preparation. In those trials it is co-administered with dasatinib, a prescription-only tyrosine kinase inhibitor.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
Generally well tolerated at supplement amounts, with headache and gastrointestinal upset reported. High intravenous doses have caused renal toxicity in early oncology studies. Quercetin inhibits CYP3A4 and P-glycoprotein, raising exposure to co-administered substrates. In the senolytic trials the safety profile is dominated by dasatinib rather than by quercetin.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral capsule of quercetin aglycone, dihydrate or phytosome complex
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Formulation matters more than the label suggests: plain aglycone, rutin and phospholipid phytosome complexes differ substantially in absorption, and the senolytic trials used a defined phytosome preparation. In those trials it is co-administered with dasatinib, a prescription-only tyrosine kinase inhibitor.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
25 products list this as an active ingredient in the United States drug directory. 5 of them contain it and nothing else.
FDA National Drug Code directory · 43742-1954 · read 2026-08-29
They are sold as extract, liquid, powder and tablet, chewable, taken oral.
FDA National Drug Code directory · 43742-1954 · read 2026-08-29
24 published labels name it as an active ingredient. 4 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 12a0adc6-a13c-441c-9252-9d5170d6636a · read 2026-08-29
Those labels are classed as human otc drug and human prescription drug.
US prescribing information · 12a0adc6-a13c-441c-9252-9d5170d6636a · read 2026-08-29
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
Watching one thing carefully can tell you whether it moved. It cannot tell you what moved it.
This is sold without a prescription, so a person can sensibly watch one thing and see whether it moves.
Pick one goal. One goal only. Two at once cannot be told apart afterwards.
Pick one thing to watch. Registered studies measured things like: plasma il 6; brachial artery flow mediated dilation; glucose tolerance following a maltose tolerance test.
Measure before you start. Take the same measurement several times first. One reading is not a starting point.
Know the swing. Write down how much it moves on its own across a normal week.
Change one thing. Change nothing else at the same time, including training and sleep.
Give it the study length. No finished study window is recorded, so no length is suggested here.
Track whether you took it. Missed days are the most common reason a home test shows nothing.
Read the trend. Look at the line across weeks. A single reading tells you almost nothing.
What not to measure
Anything that swings more day to day than the change you are looking for.
A wearable estimate of sleep stages, which is an estimate and not a measurement.
Weight on one morning, which mostly records water.
A feeling you did not write down before starting, such as: environmental symptoms questionnaire at high altitude.
When to stop
Stop if something new and unpleasant starts, and ask a pharmacist or doctor.
Stop if you cannot keep everything else steady, because the result will not mean anything.
Stop at the end of the window you set, and read the trend then.
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki does not work out an amount for anyone.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That quercetin taken alone clears senescent cells in humans — every human study used the dasatinib combination
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a 3 mmHg systolic reduction is clinically meaningful; the meta-analysis authors asked for that question to be tested and it has not been
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That reduced senescent cell burden in a biopsy translates into a clinical benefit; the first randomised test of that missed its primary endpoint
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Quercetin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
Pooled blood pressure reduction of 3.04 mmHg systolic across seven trials
In plain words
Adding up the randomised trials, quercetin lowered blood pressure by about 3 points systolic and 2.6 diastolic.
What was measured
Weighted mean difference in systolic and diastolic blood pressure versus placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Serban et al. pooled seven placebo-controlled randomised trials comprising nine treatment arms and 587 patients. Systolic BP fell by a weighted mean difference of -3.04 mmHg (95% CI -5.75 to -0.33, P = 0.028) and diastolic by -2.63 mmHg (95% CI -3.26 to -2.01, P < 0.001). Subgroup analysis suggested the effect was limited to, or greater at, doses above 500 mg/day. The authors themselves called for further work on whether the effect is clinically relevant.
Written into the record, not signed off as a reviewed claim
Dasatinib plus quercetin measurably cleared senescent cells from human fat
In plain words
Nine patients with diabetic kidney disease took the combination for three days, and biopsies eleven days later showed fewer worn-out cells in their fat tissue.
What was measured
p16INK4A, p21CIP1 and SA-beta-galactosidase positive cell counts in adipose biopsy
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Hickson et al. ran an open-label phase 1 pilot in nine subjects with diabetic kidney disease, mean age 68.7, giving three days of oral dasatinib 100 mg plus quercetin 1000 mg. Adipose tissue, skin biopsies and blood were collected before and 11 days after. Adipose senescent cell burden fell, with decreases in p16INK4A- and p21CIP1-expressing cells, cells with senescence-associated beta-galactosidase activity, and adipocyte progenitors with limited replicative potential. This was the first peer-reviewed demonstration that senolytics reduce senescent cells in humans. It is nine people, open-label, with no control group, and it is the combination rather than quercetin alone.
Written into the record, not signed off as a reviewed claim
The first randomised senolytic trial missed its primary endpoint
In plain words
When the combination was finally tested properly against a control in 60 postmenopausal women, the main bone measurement did not move.
What was measured
Percentage change in serum CTx at 20 weeks
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Khosla and colleagues ran a phase 2 randomised controlled trial of intermittent dasatinib plus quercetin in 60 postmenopausal women. The primary endpoint, percentage change at 20 weeks in the bone resorption marker CTx, did not differ between groups: median -4.1% (IQR -13.2 to 2.6) on D+Q against -7.7% (IQR -20.1 to 14.3) on control, P = 0.611. The bone formation marker P1NP rose significantly against control at 2 weeks (+16%, P = 0.020) and 4 weeks (+16%, P = 0.024) but not at 20 weeks. No serious adverse events occurred. In exploratory analysis restricted to women in the highest tertile of T cell p16 mRNA, D+Q increased P1NP by 34% and reduced CTx by 11% at two weeks and raised radius bone mineral density by 2.7% at 20 weeks. The authors were explicit that the overall group showed no reduction in bone resorption and that the senescent-cell-burden hypothesis needs its own test.
Written into the record, not signed off as a reviewed claim
The endurance-performance claim is a 2% improvement, called trivial to small
In plain words
Pooling eleven trials, quercetin improved endurance by about 2%, which the authors themselves described as between trivial and small.
What was measured
That quercetin is an ergogenic aid of practical significance for endurance athletes
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Kressler et al. pooled eleven studies with data on 254 human subjects, median treatment duration 11 days at a median 1,000 mg/day. The combined effect size for VO2max and endurance performance favoured quercetin (ES = 0.15, P = 0.021, 95% CI 0.02 to 0.27) but the magnitude was described as between trivial and small, equating to approximately a 2% improvement over placebo. Meta-regression against fitness level and against achieved plasma quercetin concentration was not significant, meaning the effect does not scale with exposure — which is what a real pharmacological effect usually does.
Written into the record, not signed off as a reviewed claim
The senolytic evidence is for a combination containing a prescription cancer drug
In plain words
Every human senolytic study used quercetin together with dasatinib, a leukaemia drug. None tested quercetin on its own.
What was measured
That quercetin taken alone as a supplement clears senescent cells in humans
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The first-in-human senolytic study, an open-label two-centre trial in 14 patients with idiopathic pulmonary fibrosis, gave dasatinib 100 mg/day plus quercetin 1250 mg/day for three days a week over three weeks, with retention and completion as its primary endpoints. The diabetic kidney disease pilot and the randomised bone trial both used the same combination. Dasatinib is a BCR-ABL tyrosine kinase inhibitor with recognised toxicities. Reading these results as evidence for the supplement on a shelf attributes the effect of a two-drug combination to one of its components, and to the one whose contribution has never been isolated.
This order is fixed in code and does not count clicks or time on the page.
What is not here
4 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A dietary flavonol with a small measured blood pressure reduction, a trivial-to-small effect on endurance, real evidence that it clears senescent cells from human fat tissue when combined with a prescription leukaemia drug, and a first randomised senolytic trial whose primary endpoint it missed.
Recorded evidence blocks (14)
Q1
What did Quercetin's largest trial (1000 people) and its longest (11 years) measure?
1000 people in Quercetin's largest registered study, 11 years in its longest registered window, measuring Frailty. ClinicalTrials.gov · 2026-09-01
20 phase2, 17 phase1, 14 na, 4 early phase1, 4 phase4, 3 phase3, 1 na or unstated; NCT00065676; 2021-08-06. Last human test completed 2026, NCT07000734.
Interpretation These counts include studies where Quercetin was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
20
phase1
17
na
14
early phase1
4
phase4
4
phase3
3
2 more recorded rows
na or unstated
1
Last recorded human testNCT07000734
2026-04-30
recorded 2026-09-01 · last checked 2026-09-04
Q2
From C. elegans to human: where has Quercetin shown lifespan?
7 recorded entries; human; tablet, oral, capsule; also "Quercetin (500 mg)", "Quercetin 1000mg", "Quercetin 1000 mg"
Show the evidence
human
NCT01881919
tablet; Quercetin dihydrate 500 mg tablet
NCT05371340
Quercetin (500 mg)
NCT05653258
Quercetin 1000mg
NCT06003270
Quercetin 1000 mg
NCT06003270
Quercetin 500 MG
NCT06018467
oral; Quercetin 1.250 mg (oral)
1 more recorded row
humanNCT07182526
capsule; Quercetin 500 mg capsule, NOW pharmacetics
recorded 2026-09-01 · last checked 2026-09-04
Q5
Did Quercetin move epigenetic age, and by how much?
epigenetic age: "This study aimed to assess the effects of Dasatinib and Quercetin (DQ) senolytic treatment on DNA methylation (DNAm), epigenetic age, and immune cell subsets." Europe PMC · epigenetic clock search · 2024-02-22
1 recorded sentence; 2024; biomarker
Show the evidence
epigenetic agePMID 38393697
2024; "This study aimed to assess the effects of Dasatinib and Quercetin (DQ) senolytic treatment on DNA methylation (DNAm), epigenetic age, and immune cell subsets."
recorded 2024-02-22 · last checked 2026-09-04
Q6
More Quercetin was worse in human: at what point?
Hormetic in human: "However, its clinical translation is hampered by the BBB permeability and the hormetic dose-response properties of quercetin." Europe PMC · dose-response search · 2026-07-27
5 recorded sentences naming Quercetin; hormetic, dose-response
Show the evidence
hormetic
PMID 42629256
"However, its clinical translation is hampered by the BBB permeability and the hormetic dose-response properties of quercetin."
PMID 40287100
"While the hormetic effects of kaempferol are biologically diverse, there has been a strong focus on age-related endpoints affecting numerous organ systems and endpoints, indicating that kaempferol is a senolytic agent, showing similar properties as quercetin and fisetin."
PMID 38142767
"Consequently, the present paper provides the first assessment of quercetin-induced hormetic concentration/dose responses, their quantitative features and mechanistic foundations, and their biological, biomedical, clinical, and public health implications."
PMID 38142767
"The findings indicate that quercetin-induced hormetic dose responses are widespread, being independent of biological model, cell type, and endpoint."
dose-responsePMID 41822595
"This meta-analysis aims to quantitatively synthesize the available evidence and examine the dose-response relationships of dietary quercetin supplementation on productive performance, egg quality traits, blood metabolites, and antioxidant defenses in laying hens."
recorded 2026-07-27 · last checked 2026-09-04
Q7
Could one person measure Quercetin's effect on plasma il 6?
glucose tolerance following a maltose tolerance test; 2026-09-01
environmental symptoms questionnaire at high altitude; 2026-09-01
lake louise ams scoring system at high altitude; 2026-09-01
army physical fitness test at high altitude; 2026-09-01
14 more recorded rows
biomarkers
uphill hike at high altitude; 2026-09-01
biomarkers
frailty; 2026-09-01
biomarkers
oxidative stress markers; 2026-09-01
biomarkers
inflammatory markers; 2026-09-01
biomarkers
feasibility number of enrolled per month; 2026-09-01
biomarkers
eligibility proportion eligible after screening; 2026-09-01
biomarkers
c terminal telopeptide of type i collagen; 2026-09-01
biomarkers
days of stay at hospital after treatment and discharge; 2026-09-01
biomarkers
serum zinc before and after treatment; 2026-09-01
biomarkers
safety and tolerability; 2026-09-01
biomarkers
mortality rate; 2026-09-01
biomarkers
need for icu admission; 2026-09-01
biomarkers
treatment safety; 2026-09-01
biomarkers
complete recovery from covid 19 resolution of symptoms; 2026-09-01
human trials at or under30
26
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT02989129; EARLY_PHASE1; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q8
Which of admission to a hospital for further advanced treatment, army physical fitness test at high altitude and blood vessel dilation did Quercetin's trials measure?
admission to a hospital for further advanced treatment, army physical fitness test at high altitude and blood vessel dilation lead 40 outcome terms across Quercetin's trials. ClinicalTrials.gov · 2026-09-01
Interpretation environmental symptoms questionnaire at high altitude, lake louise ams scoring system at high altitude, army physical fitness test at high altitude, uphill hike at high altitude, frailty and oxidative stress markers follow.
Show the evidence
plasma il 6
1
brachial artery flow mediated dilation
1
glucose tolerance following a maltose tolerance test
1
environmental symptoms questionnaire at high altitude
1
lake louise ams scoring system at high altitude
1
army physical fitness test at high altitude
1
14 more recorded rows
uphill hike at high altitude
1
frailty
1
oxidative stress markers
1
inflammatory markers
1
feasibility number of enrolled per month
1
eligibility proportion eligible after screening
1
c terminal telopeptide of type i collagen
1
days of stay at hospital after treatment and discharge
1
serum zinc before and after treatment
1
safety and tolerability
1
mortality rate
1
need for icu admission
1
treatment safety
1
complete recovery from covid 19 resolution of symptoms
1
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which of Quercetin's 14 ongoing trials reports first?
Safety and Tolerability; Insulin sensitivity; latest 2031-08-15
Show the evidence
Trial
NCT04785300
"ALSENLITE: Senolytics for Alzheimer's Disease"; n 20; "Safety and Tolerability"; 2026-12
NCT05653258
"Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects"; n 160; "Insulin sensitivity"; 2028-02-01
NCT05838560
"Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders"; n 40; "Number of participants who successfully completed and safely tolerated the intervention"; 2027-10-01
NCT06018467
"Senolytics to Improve Osteoporosis Therapy"; n 120; "Bone resorption marker CTX"; 2026-04-30
NCT06230861
"Effects of Quercetin on Cardiometabolic Outcomes"; n 40; "Systolic blood pressure"; 2026-12-01
NCT06683534
"Palmitic Acid and Human Microvascular Function"; n 40; "Change in blood vessel dilation"; 2030-12
8 further recorded trials
NCT06940297
"Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma"; n 44; "Minimal residual disease (MRD) negativity rate"; 2031-08-15
NCT07025226
"Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease"; n 30; "Completion of 3 cycles"; 2027-09-01
NCT07144293
"Improving Physical Ability and Cellular Senescence Elimination in HIV"; n 82; "Occurrence of Grade 2 or higher adverse events (AEs) after initiation of study treatment."; 2026-09-01
NCT07182526
"Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome"; n 150; "Change in Hormonal Profile (LH, FSH, Testosterone) from Baseline"; 2026-05-01
NCT07433621
"Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency"; n 12; "Safety of quercetin in patients with XIAP deficiency"; 2029-06
NCT07466420
"Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases."; n 100; "Change in Blood Leukocyte Telomere length"; 2029-01-31
NCT07628972
"Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)"; n 12; "Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0"; 2028-09
NCT07760506
"The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health"; n 60; "Inflammaging (CIMKDM)"; 2028-08
recorded 2026-09-01 · last checked 2026-09-04
Q10
Which running trial of Quercetin could settle insulin sensitivity?
NCT05653258 measures Insulin sensitivity, reading out 2028-02-01.
1 open trial; n 160; "Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects"
Show the evidence
TrialNCT05653258
"Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects"; n 160; "Insulin sensitivity"; 2028-02-01
Q11
Which 21 trials of Quercetin posted no result?
Posted no result
21 of 21 completed trials
Registrations
NCT00402623, NCT01168739, NCT01348204, NCT01732393, NCT01691404 and NCT01185067, and 15 more
Completion dates
oldest 2006-01; newest 2024-08-31
Show the evidence
Trial
NCT00402623
2006-01
NCT01168739
2010-03
NCT01348204
2011-11
NCT01732393
2012-01
NCT01691404
2013-03
NCT01185067
2014-02-24
14 further recorded trials
NCT01438320
2014-06
NCT01881919
2014-11
NCT01839344
2015-03
NCT02226484
2016-06
NCT05371340
2020-04-27
NCT05037240
2021-05-25
NCT01912820
2021-06-10
NCT04851821
2021-06-30
NCT00065676
2021-08-06
NCT04853199
2021-08-30
NCT01720147
2021-10-26
NCT02652052
2023-05-23
NCT06209229
2023-10-01
NCT05877235
2024-06-23
Q12
At the median, Quercetin's trials enrolled 33 people — anything larger?
Median enrolment
33
Largest enrolment
1000
Registered trials counted
57
Q13
Was Quercetin studied with fasting, caloric restriction and exercise?
fasting, caloric restriction and exercise are named in Quercetin's label sentences: "Fasting blood glucose (p < 0.001), insulin (p = 0.02), and homeostatic model assessment of insulin resistance (p = 0.009) decreased within the quercetin group; however, no significant differences were observed compared with the placebo group (p = 0.074, p = 0.226, p = 0.22, respectively)." openfda-label+europepmc · 2025-11-02
3 recorded statements; fasting, caloric restriction, exercise
Show the evidence
fasting
Fasting blood glucose (p < 0.001), insulin (p = 0.02), and homeostatic model assessment of insulin resistance (p = 0.009) decreased within the quercetin group; however, no significant differences were observed compared with the placebo group (p = 0.074, p = 0.226, p = 0.22, respectively).
caloric restriction
We conducted the first preclinical trial in a relevant middle-aged nonhuman primate (NHP) model to allow estimation of the main translatable effects of the senolytic combination dasatinib (D) and quercetin (Q), with and without caloric restriction (CR).
exercise
We conducted a double-blind, placebo-controlled crossover trial (n = 13, middle-aged men) combining acute high-intensity interval exercise (HIIE) with 21-day quercetin supplementation (1000 mg/day).
recorded 2025-11-02 · last checked 2026-09-04
Q14
What is recorded about Quercetin and autophagy?
"Notably, quercetin treatment was associated with the inhibition of this autophagic dysregulation and attenuated the LTA-induced disruption of TJ protein expression." — where Quercetin and autophagy appear together. Europe PMC · pathway abstract search · 2026-07-13
"Notably, quercetin treatment was associated with the inhibition of this autophagic dysregulation and attenuated the LTA-induced disruption of TJ protein expression."
mTORPMID 42090971
"Further mechanistic studies revealed that both quercetin and Compound C (CC, an AMPK inhibitor) reduced autophagy levels and mitigated the LTA-induced decline in key TJ proteins, suggesting that quercetin is associated with the attenuation of LTA-induced TJ integrity disruption under inflammatory stress, which correlates with modulated changes in AMPK phosphorylation and the mTOR signaling…"
AMPKPMID 42090971
"Further mechanistic studies revealed that both quercetin and Compound C (CC, an AMPK inhibitor) reduced autophagy levels and mitigated the LTA-induced decline in key TJ proteins, suggesting that quercetin is associated with the attenuation of LTA-induced TJ integrity disruption under inflammatory stress, which correlates with modulated changes in AMPK phosphorylation and the mTOR signaling…"
autophagyPMID 42090971
"Further mechanistic studies revealed that both quercetin and Compound C (CC, an AMPK inhibitor) reduced autophagy levels and mitigated the LTA-induced decline in key TJ proteins, suggesting that quercetin is associated with the attenuation of LTA-induced TJ integrity disruption under inflammatory stress, which correlates with modulated changes in AMPK phosphorylation and the mTOR signaling…"
sirtuinPMID 42196199
"Preclinical studies demonstrate that natural compounds (resveratrol, quercetin, curcumin, ginsenosides, tanshinone IIA, bergenin, swietenine) and synthetic SIRT1 activators (SRT1720, anilinopyridine derivatives) attenuate cardiac injury and improve function."
mTORPMID 40009568
"Therefore, our study aimed to investigate the involvement of sirtuin 3 (SIRT3) and the autophagy-dependent form of cell death, ferroptosis, in the pathogenesis of OSCC, and observe the impacts of quercetin on ferroptosis and SIRT3/AMPK/mTOR-mediated autophagy."
7 more recorded rows
AMPKPMID 40009568
"Therefore, our study aimed to investigate the involvement of sirtuin 3 (SIRT3) and the autophagy-dependent form of cell death, ferroptosis, in the pathogenesis of OSCC, and observe the impacts of quercetin on ferroptosis and SIRT3/AMPK/mTOR-mediated autophagy."
sirtuinPMID 40009568
"Therefore, our study aimed to investigate the involvement of sirtuin 3 (SIRT3) and the autophagy-dependent form of cell death, ferroptosis, in the pathogenesis of OSCC, and observe the impacts of quercetin on ferroptosis and SIRT3/AMPK/mTOR-mediated autophagy."
autophagyPMID 40009568
"Therefore, our study aimed to investigate the involvement of sirtuin 3 (SIRT3) and the autophagy-dependent form of cell death, ferroptosis, in the pathogenesis of OSCC, and observe the impacts of quercetin on ferroptosis and SIRT3/AMPK/mTOR-mediated autophagy."
AMPKPMID 40009568
"Autophagy and AMPK inhibitors, or SIRT3 deletion significantly antagonized the impacts of quercetin on the autophagy-mediated ferroptosis in cancer cells."
sirtuinPMID 40009568
"Autophagy and AMPK inhibitors, or SIRT3 deletion significantly antagonized the impacts of quercetin on the autophagy-mediated ferroptosis in cancer cells."
mTORPMID 40009568
"SIRT3 overexpression activated the AMPK/mTOR pathway and triggered ATG16L1-mediated autophagy, promoting ferroptosis in SCC15 cells, and we proposed that quercetin may be a promising therapeutic drug for OSCC."
NAD+PMID 41714893
"Interventions targeting this axis-NAD⁺ precursors (NMN/NR), Sirtuin activators (resveratrol/quercetin), and lifestyle strategies (intermittent fasting/exercise)-demonstrate efficacy in preclinical models: NMN restores sperm quality (+40% normality) and testosterone synthesis; resveratrol reduces sperm DNA fragmentation by 45% via SIRT3 activation."
senolytic
PMID 42392409
"Pharmacological interventions such as quercetin (a p38 MAPK inhibitor), melatonin (an Nrf2 activator), and senolytic agents illustrate the potential to disrupt the senescence-PCD axis."
PMID 42378907
"We critically evaluate the preclinical efficacy of senolytics (eg, dasatinib + quercetin, navitoclax, fisetin), and senomorphics (eg, rapamycin, metformin, melatonin, NLRP3 inhibitors) in preserving ovarian reserve, mitigating SASP-driven inflammation and fibrosis, and extending reproductive lifespan."
PMID 42442548
"Dasatinib and quercetin, two established senolytic agents, were co-encapsulated into uPAR-targeted hybrid nanoparticles to selectively eliminate senescent cells, reduce inflammation, and restore metabolic homeostasis, presenting a promising therapeutic strategy for obesity- and aging-associated disorders."
recorded 2026-07-13 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.